Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Faes Farma, S.A.
This is a single center, Phase 1 study that utilizes a randomized, multiple-dose, double-blind, 5-way crossover design with a placebo control and two active controls. A minimum seven day washout period following four days of dosing for each of the five treatments.
Age
18–45
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy subjects with no clinically significant findings note on screening assessments including medical history, physical examination and laboratory results
You may not be if
Clinically significant medical condition
Clinically significant history of ECG abnormalities or family history of QTc interval syndrome
Use of tobacco and/or nicotine products \>3 months prior to screening
Use of any prescription medications within 14 days prior to screening
Use of over the counter medications (including herbal products) within 7 days prior to screening
Clareo Health | A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
